Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286


Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNS

Author(s): Paulus S. Rommer and Uwe K. Zettl

Volume 28, Issue 6, 2022

Published on: 18 February, 2022

Page: [427 - 427] Pages: 1

DOI: 10.2174/138161282806220218141218

Next »
Of men, not mice. Nat Med 2013; 19(4): 379-9.
Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110(9): 3507-12.
Selmi C, Mix E, Zettl UK. A clear look at the neuroimmunology of multiple sclerosis and beyond. Autoimmun Rev 2012; 11(3): 159-62.
Strech D, Dirnagl U. 3Rs missing: animal research without scientific value is unethical. BMJ Open Sci 2019; 3(1) bmjos
Rommer P, Zettl UK. Treatment options in multiple sclerosis and neuromyelitis optica spectrum disorders. Curr Pharm Des 2022; 28(6): 428-36.
Steinmaurer A, Wimmer I, Berger T, Rommer PS, Sellner J. Bruton’s tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis. Curr Pharm Des 2022; 28(6): 437-44.
Gebhardt M, Kropp P, Hoffmann F, Zettl UK. Headache in multiple sclerosis - pharmacological aspects. Curr Pharm Des 2022; 28(6): 445-53.
Macher S, Bsteh G, Berger T, Höftberger R. Diagnostic approach and treatment regimens in adult patients suffering from antibody-mediated or paraneoplastic encephalitis. Curr Pharm Des 2022; 28(6): 454-67.
Frahm N, Hecker M, Zettl UK. Polypharmacy in chronic neurological diseases: multiple sclerosis, dementia and Parkinson’s disease. Curr Pharm Des 2021; 27(38): 4008-16.

© 2023 Bentham Science Publishers | Privacy Policy